Vanda anxiety drug misses late-stage trial goal, pauses program

• VQW-765 failed both its primary endpoint (anxiety reduction in public-speaking test) and a key secondary endpoint in the broader study population
• The late-stage trial results did not confirm promising findings from an earlier mid-stage trial that had suggested the drug could reduce anxiety symptoms
• Despite the efficacy failure, the drug was reported as safe and well tolerated, consistent with prior studies; Vanda will review the full dataset before determining next steps

Summary

Key Development:

Vanda Pharmaceuticals announced on October 14 that its experimental drug VQW-765 for social anxiety disorder failed to meet the primary endpoint in a late-stage clinical trial. The drug did not demonstrate statistically significant reduction in anxiety compared to placebo during a public-speaking stress test.

Trial Details:

• Enrolled 546 adults with social anxiety disorder
• Conducted at approximately 30 sites across the United States
• Failed both primary and key secondary endpoints in the broader study population
• Drug was deemed safe and well-tolerated, consistent with earlier studies

Background:

The late-stage trial was designed to confirm positive results from an earlier mid-stage study that had suggested VQW-765 could reduce anxiety symptoms. However, the Phase 3 results did not replicate these earlier findings.

Company Response:

Vanda has placed the entire VQW-765 development program on hold pending comprehensive analysis of the complete dataset. The company will review the data before determining next steps.

Market Implications:

This represents a significant setback for Vanda Pharmaceuticals, as late-stage trial failures typically result in substantial share price declines and force companies to refocus resources on other pipeline candidates. The failure to replicate mid-stage results raises questions about the drug's efficacy profile and represents a lost opportunity in the social anxiety disorder treatment market. Investors should expect potential negative impact on Vanda's valuation and may see management reassess strategic priorities for the company's development portfolio.